Abstract
Psoriasis (PsO), psoriatic arthritis (PsA), and axial spondyloarthritis (AxSpA) are chronic systemic inflammatory disorders closely associated with cardiovascular (CV) disease. Here, we evaluated the effect of secukinumab on CV risk parameters in 9197 patients included in a post hoc analysis of 19 pooled phase 3/4 secukinumab studies in PsO (n = 4742), PsA (n = 2475), and AxSpA (n = 1980). Traditional (body mass index [BMI], fasting glucose, blood pressure, cholesterol, and lipids) and inflammatory CV risk parameters (high-sensitivity C-reactive protein [hsCRP] and neutrophil-lymphocyte ratio [NLR]) were assessed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
